Improved enzyme immunoassay for human basic fibroblast growth factor using a new enhanced chemiluminescence system.
An enhanced chemiluminescence reaction has been incorporated into an enzyme immunoassay (EIA) for human basic fibroblast growth factor (hbFGF). We developed a new luminol derivative, designated L-012 and a new enhancer, 4-(4-hydroxyphenyl)thiazole. Using these compounds, the detection limit of hbFGF was improved to 0.1 pg/assay, which was 10-20 and 2 times better than the o-phenylenediamine colorimetric and luminol chemiluminescence assays, respectively. The average concentration of bFGF in sera from 25 normal volunteers was 5.9 pg/ml. On the other hand, serum bFGF levels were elevated in renal, lung and brain tumor patients. The data presented here indicate that the serum bFGF level could be a useful diagnostic marker for these tumors. Furthermore, these new compounds could easily be applied to any other EIA that uses horse radish peroxidase to improve sensitivity.
Ii
M
M
Pharmaceutical Research Division, Takeda Chemical Industries, Osaka, Japan.
Yoshida
H
H
Aramaki
Y
Y
Masuya
H
H
Hada
T
T
Terada
M
M
Hatanaka
M
M
Ichimori
Y
Y
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000097:blood*; D001932:Brain Neoplasms / Q000097:blood; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D007124:Immunoenzyme Techniques; D007202:Indicators and Reagents; D007680:Kidney Neoplasms / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood; D008163:Luminescent Measurements; D008165:Luminol / Q000031:analogs & derivatives; D008175:Lung Neoplasms / Q000097:blood; D009369:Neoplasms / Q000097:blood*; D012016:Reference Values; D013274:Stomach Neoplasms / Q000097:blood; D001749:Urinary Bladder Neoplasms / Q000097:blood
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D007202:Indicators and Reagents; D016222:Fibroblast Growth Factor 2; C081614:L 012; D008165:Luminol